0000950170-22-012267.txt : 20220628 0000950170-22-012267.hdr.sgml : 20220628 20220628161607 ACCESSION NUMBER: 0000950170-22-012267 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220627 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20220628 DATE AS OF CHANGE: 20220628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allena Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001624658 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 452729920 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38268 FILM NUMBER: 221050317 BUSINESS ADDRESS: STREET 1: ONE NEWTON EXECUTIVE PARK STREET 2: SUITE 202 CITY: NEWTON STATE: MA ZIP: 02462 BUSINESS PHONE: 617-467-4577 MAIL ADDRESS: STREET 1: ONE NEWTON EXECUTIVE PARK STREET 2: SUITE 202 CITY: NEWTON STATE: MA ZIP: 02462 8-K 1 alna-20220627.htm 8-K 8-K
0001624658false00016246582022-06-272022-06-27

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 27, 2022

 

 

Allena Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38268

45-2729920

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

One Newton Executive Park

Suite 202

 

Newton, Massachusetts

 

02462

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 467-4577

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

ALNA

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

Item 1.02 Termination of a Material Definitive Agreement.

Allena Pharmaceuticals, Inc. (the “Company”) previously entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (the “Sales Agent”) on December 23, 2021, pursuant to which the Company was able to issue and sell from time to time in an “at-the-market” offering shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). As of June 27, 2022, 6,804,888 shares of Common Stock have been issued and sold under the Sales Agreement.

 

On June 27, 2022, the Company provided notice to the Sales Agent that it was terminating the Sales Agreement, effective immediately. The Sales Agreement provided for termination thereof by either party upon ten (10) calendar days’ prior written notice to the other party. The Company will not incur any early termination penalties in connection with the termination of the Sale Agreement.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

 

Date:

June 28, 2022

By:

/s/ Richard Katz

 

 

 

Richard Katz, M.D.
Chief Financial Officer

 

 EX-101.LAB 2 alna-20220627_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 3 alna-20220627.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 4 alna-20220627_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document And Entity Information
Jun. 27, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 27, 2022
Entity Registrant Name Allena Pharmaceuticals, Inc.
Entity Central Index Key 0001624658
Entity Emerging Growth Company true
Entity File Number 001-38268
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-2729920
Entity Address, Address Line One One Newton Executive Park
Entity Address, Address Line Two Suite 202
Entity Address, City or Town Newton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02462
City Area Code (617)
Local Phone Number 467-4577
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ALNA
Security Exchange Name NASDAQ
XML 6 alna-20220627_htm.xml IDEA: XBRL DOCUMENT 0001624658 2022-06-27 2022-06-27 0001624658 false 8-K 2022-06-27 Allena Pharmaceuticals, Inc. DE 001-38268 45-2729920 One Newton Executive Park Suite 202 Newton MA 02462 (617) 467-4577 Not Applicable false false false false Common Stock, par value $0.001 per share ALNA NASDAQ true true EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports alna-20220627.htm alna-20220627.xsd alna-20220627_lab.xml alna-20220627_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "alna-20220627.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "alna-20220627.htm" ] }, "labelLink": { "local": [ "alna-20220627_lab.xml" ] }, "presentationLink": { "local": [ "alna-20220627_pre.xml" ] }, "schema": { "local": [ "alna-20220627.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alna", "nsuri": "http://www.allenapharma.com/20220627", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alna-20220627.htm", "contextRef": "C_bcef2b91-d0ef-4e54-bbf7-ec4745218ce4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alna-20220627.htm", "contextRef": "C_bcef2b91-d0ef-4e54-bbf7-ec4745218ce4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.allenapharma.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0000950170-22-012267-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-012267-xbrl.zip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end